Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Larimar Therapeutics, Inc. (LRMR) had Return on Tangible Equity of -21.84% for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-26.18M |
|
-- |
|
-- |
|
$27.79M |
|
$-27.79M |
|
$1.61M |
|
$-26.18M |
|
$-26.18M |
|
$-26.18M |
|
$-26.18M |
|
$-26.18M |
|
$-26.18M |
|
$-27.79M |
|
$-28.17M |
|
64.03M |
|
64.03M |
|
$-0.41 |
|
$-0.41 |
|
| Balance Sheet Financials | |
$145.56M |
|
$0.80M |
|
$4.43M |
|
$149.99M |
|
$26.65M |
|
-- |
|
$3.48M |
|
$30.13M |
|
$119.85M |
|
$119.85M |
|
$119.85M |
|
64.03M |
|
| Cash Flow Statement Financials | |
$-45.92M |
|
$33.29M |
|
-- |
|
$33.82M |
|
$21.19M |
|
$-12.63M |
|
$3.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.46 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-45.99M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.84% |
|
|
Return on Tangible Equity |
-21.84% |
-17.46% |
|
-21.84% |
|
$1.87 |
|
$-0.72 |
|
$-0.72 |
|